With the acquisition of the remaining 51% shares by ALS, we are excited to join the ALS group and contribute to strengthening its pharmaceutical footprint in Europe.
learn more
Since March 2024, Nuvisan has become the first Gyrolab® certified CRO in the EU.
Nuvisan has received a grant from the Gates Foundation for a multi-target drug discovery program.
learn more
Nuvisan announces rebranding and web redesign
02 Apr 2025
ALS takes ownership of Nuvisan
25 Mar 2024
Contact Us
Rechercher
